<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964573</url>
  </required_header>
  <id_info>
    <org_study_id>SP0885</org_study_id>
    <nct_id>NCT01964573</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects</brief_title>
  <official_title>A Single-site, Randomized, Double-blind, Placebo-controlled, Repeated-dose Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in 2 Different Dosages (2 mg / 24 Hours [10 cm2], 4 mg / 24 Hours [20 cm2]) in Healthy Korean Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to investigate the PK (Pharmacokinetic) of repeated-dose
      applications of the Rotigotine transdermal patch in healthy young male and female Korean
      subjects to be submitted to MFDS for new drug application approval.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to 24 hours at steady-state (AUC (0-24), ss) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to 24 hours at steady-state (AUC (0-24), ss) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to 24 hours at steady-state normalized by Body Weight (AUC (0-24), ss, norm (BW)) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to 24 hours at steady-state normalized by Body Weight (AUC (0-24), ss, norm (BW)) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration normalized by Body Weight (Cmax, norm (BW)) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration normalized by Body Weight (Cmax, norm (BW)) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to 24 hours at steady-state normalized by apparent-dose (AUC (0-24), ss, norm (apparent-dose)) of unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to 24 hours at steady-state normalized by apparent-dose (AUC (0-24), ss, norm (apparent-dose)) of total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration normalized by apparent-dose (Cmax, norm (apparent-dose)) of unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration normalized by apparent-dose (Cmax, norm (apparent-dose)) of total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to 24 hours at steady-state normalized by drug content (AUC (0-24), ss, norm (mgdc)) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to 24 hours at steady-state normalized by drug content (AUC (0-24), ss, norm (mgdc)) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration normalized by drug content of patch (Cmax, norm (mgdc)) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration normalized by drug content of patch (Cmax, norm (mgdc)) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t ½) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t ½) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration during a dosing interval at steady-state (t max, ss) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration during a dosing interval at steady-state (t max, ss) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CL/f) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CL/f) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance normalized by Body Weight (CL/f norm (BW)) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance normalized by Body Weight (CL/f norm (BW)) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance normalized by apparent-dose (CL/f norm (apparent-dose)) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance normalized by apparent-dose (CL/f norm (apparent-dose)) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/f) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/f) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution normalized by Body Weight (Vz/f norm (BW)) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution normalized by Body Weight (Vz/f norm (BW)) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 predose, and 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after patch application at Day 3 and 6 and 25, 26, 28, 30, 33 and 36, 48, 60, 72 hours after patch application on Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at steady-state directly before patch removal (C (24), ss) for total Despropyl Rotigotine</measure>
    <time_frame>Directly before patch removal at Day 2 to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at steady-state directly before patch removal (C (24), ss) for total Desthienyl Rotigotine</measure>
    <time_frame>Directly before patch removal at Day 2 to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at steady-state 30 hours after last patch application (C (30 h), ss) for total Despropyl Rotigotine</measure>
    <time_frame>At day 7 at 30 hours after last patch application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at steady-state 30 hours after last patch application (C (30 h), ss) for total Desthienyl Rotigotine</measure>
    <time_frame>At day 7 at 30 hours after last patch application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount excreted into urine from 0 to 24 hours at steady-state (Ae (0-24), ss) for unconjungated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 from 0 to after 24 hours of patch application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount excreted into urine from 0 to 24 hours at steady-state (Ae (0-24), ss) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 from 0 to after 24 hours of patch application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount excreted into urine from 0 to 24 hours at steady-state (Ae (0-24), ss) for total Despropyl Rotigotine</measure>
    <time_frame>Day 3 and Day 6 from 0 to after 24 hours of patch application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount excreted into urine from 0 to 24 hours at steady-state (Ae (0-24), ss) for total Desthienyl Rotigotine</measure>
    <time_frame>Day 3 and Day 6 from 0 to after 24 hours of patch application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLR) for unconjugated Rotigotine</measure>
    <time_frame>Day 3 and Day 6 from 0 to after 24 hours of patch application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLR) for total Rotigotine</measure>
    <time_frame>Day 3 and Day 6 from 0 to after 24 hours of patch application</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Rotigotine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to rotigotine will be administered in the same way as within the Rotigotine group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotigotine</intervention_name>
    <description>Day 1-3: 2 mg patch once daily
Day 4-6: 4 mg patch once daily</description>
    <arm_group_label>Rotigotine group</arm_group_label>
    <other_name>Neupro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.
Frequency:
Day 1-3: 2 mg patch once daily
Day 4-6: 4 mg patch once daily</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female and aged between 19 and 45 years of age (inclusive)

          -  Subject is healthy (no clinically relevant findings in any of the investigations of
             the pre-examination) as judged by the investigator

          -  Subject is of normal body weight as determined by a Body Mass Index (BMI) between 18
             and 28 kg / m²

          -  Subject is Korean (both parents are pure Korean)

        Exclusion Criteria:

          -  Subject has had a history of drug or alcohol abuse within the last 2 years

          -  Subject has had a history of transient ischemic attack or stroke within the last 12
             months

          -  Subject has a history or current condition of Epilepsy and / or seizures

          -  Subject has a history of significant skin hypersensitivity to adhesives or other
             transdermal products or recently unsolved Contact Dermatitis

          -  Subject has a history or present condition of an Atopic or Eczematous Dermatitis,
             Psoriasis, and / or an active skin disease

          -  Female subject is pregnant or lactating

          -  Subject has any medical or psychiatric condition that, in the opinion of the
             investigator, could jeopardize or would compromise the subject's ability to
             participate in this trial

          -  Subject has a QTcB (according to Bazett´s formula) interval of ≥ 450 ms for female or
             ≥ 430 ms for male or any other clinically relevant Electrocardiogram (ECG) finding

          -  Subject has any clinically relevant abnormality in the physical examination, or any
             clinically relevant deviation from the normal range in the clinical chemistry,
             hematology, or urinalysis

          -  Subject has a relevant hepatic dysfunction (total Bilirubin &gt; 2 mg /dL or Alanine
             Aminotransferase [ALT] or Aspartate Aminotransferase [AST] greater than 2 times the
             upper limit of the normal reference range)

          -  Subject has a positive test for Human Immunodeficiency Virus antibodies (HIV)-1/2Ab,
             Hepatitis B surface Antigen (HBsAg) or Hepatitis C Virus Antibody (HCV-Ab)

          -  Subject has a positive test for alcohol or drugs

          -  Subject consumes more than 150 g of alcohol / week

          -  Subject has made a blood donation or had a comparable blood loss (&gt; 400 ml) within the
             last 3 months

          -  Subject smokes more than 5 cigarettes per day or has done so within previous 6 months

          -  Subject has a clinically relevant allergy

          -  Subject is taking any medication (excluding oral hormonal contraceptive) currently or
             within 2 weeks prior to the first day of dosing (with the exception of Acetaminophen
             [up to 1000 mg per day per os] which may have been taken up to 48 hours prior to
             commencement of dosing)

          -  Female subject is currently taking an oral hormonal contraceptive but less than 2
             months

          -  Subject has a symptomatic orthostatic hypotension with a decrease of Blood Pressure
             (BP) from supine to standing position of ≥ 20 mmHg in systolic BP or of ≥ 10 mmHg in
             diastolic BP after 1 and / or 3 minutes

          -  Subject has a pulse rate at rest less than 45 beats per minute or more than 100 beats
             per minute (measured in supine position)

          -  Subject has a systolic Blood Pressure (BP) lower than 100 mmHg or higher than 150 mmHg
             or diastolic BP higher than 95 mmHg (measured in supine position)

          -  Subject has a current or a history of clinically relevant motor disturbance,
             impairment of memory, sleep disturbance or neurodegenerative disease (e.g. , Alzheimer
             Dementia, Diffuse, Lewy Body Dementia, Amyotrophic Lateral Sclerosis [ALS], Multiple
             Sclerosis)

          -  Subject has taken herbal medicine therapy within the last 2 weeks

          -  Subject consumes more than 3 cups (more than 450 ml) of caffeinated beverages per day
             within the last 2 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2013</study_first_submitted>
  <study_first_submitted_qc>October 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <last_update_submitted>October 17, 2014</last_update_submitted>
  <last_update_submitted_qc>October 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Rotigotine</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotigotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

